Y90 radioembolization of colorectal cancer liver metastases: response assessment by contrast-enhanced computed tomography with or without PET-CT guidance

Clinical Imaging
Michael VouchePatrick Flamen

Abstract

To compare various computed tomography (CT) parameters to the positron emission tomography with computed tomography (PET-CT) response, with or without PET guidance for the response assessment of colorectal cancer (CRC) metastases treated by Y90 radioembolization. Thirty-six CRC metastases were retrospectively evaluated on 18F-Fluoro-Deoxy-Glucose PET-CT and contrast-enhanced computed tomography (CECT) performed at baseline and 2-3 months after Y90 radioembolization. Median SUVmax values decreased from 11.39 to 6.71 after radioembolization (P<.001), and 23/36 (64%) metastases were categorized metabolic responses according to European Organisation for Research and Treatment of Cancer criteria. Only a decrease of the mean attenuation in the structural (P<.001) and metabolic active volume (P<.001) was observed. The change in these criteria was correlated with the change of SUVmax.

References

Feb 16, 2000·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·H YoungP Price
Mar 18, 2005·European Journal of Nuclear Medicine and Molecular Imaging·Maren BienertNorbert Avril
Nov 23, 2006·Cancer Imaging : the Official Publication of the International Cancer Imaging Society·Lioe-Fee de Geus-OeiWim J G Oyen
Feb 22, 2007·AJR. American Journal of Roentgenology·Frank H MillerRiad Salem
May 29, 2007·Surgical Oncology·Vijay P KhatriNicholas J Petrelli
Oct 9, 2007·Cancer Imaging : the Official Publication of the International Cancer Imaging Society·Wolfgang SchimaThomas Gruenberger
Mar 20, 2008·Radiographics : a Review Publication of the Radiological Society of North America, Inc·Chikako SuzukiLennart Blomqvist
Dec 23, 2008·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·E A EisenhauerJ Verweij
Jan 13, 2009·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Ahsun RiazRiad Salem
Jun 24, 2009·Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine·Richard L WahlMartin A Lodge
Jan 19, 2010·Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine·Perrine TylskiIrène Buvat
Feb 23, 2010·Seminars in Liver Disease·Riccardo Lencioni, Josep M Llovet
Nov 25, 2011·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A HendliszP Flamen
Jul 10, 2012·Current Treatment Options in Oncology·Khairuddin MemonRiad Salem
Sep 5, 2012·European Journal of Nuclear Medicine and Molecular Imaging·Linda HeijmenHanneke W M van Laarhoven
May 25, 2013·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Michael VoucheRiad Salem

❮ Previous
Next ❯

Citations

Dec 13, 2006·Clinics in Liver Disease·James F Trotter
Apr 25, 2019·Molecular Imaging and Biology : MIB : the Official Publication of the Academy of Molecular Imaging·Oke GerkeWerner Vach

❮ Previous
Next ❯

Related Concepts

Related Feeds

Carcinoma, Hepatocellular

Hepatocellular Carcinoma is a malignant cancer in liver epithelial cells. Discover the latest research on Hepatocellular Carcinoma here.

Cancer Imaging

Imaging techniques, including CT and MR, have become essential to tumor detection, diagnosis, and monitoring. Here is the latest research on cancer imaging.

Cancer Metabolism

In order for cancer cells to maintain rapid, uncontrolled cell proliferation, they must acquire a source of energy. Cancer cells acquire metabolic energy from their surrounding environment and utilize the host cell nutrients to do so. Here is the latest research on cancer metabolism.